Novel Assay Platform for 3D Microfluidic Cancer Research
Top left: ONCO-Chip 3D microfluidic plate. Top right: time sequence showing CAR-T cells interacting with 3D tumour models. Bottom: schematic and microscopy images of CAR-T killing cancer cells only (unlabelled) in different combination treatments.
Custom CAR-T development by AMSBIO.
Custom CAR-T development by AMSBIO.

Laboratory products

Novel Assay Platform for 3D Microfluidic Cancer Research

12 Oct, 2021

Published over 4 years ago. See the latest and most current information on Laboratory products.

Chimeric antigen receptor (CAR-T) cells are genetically modified T-cells that are engineered to find and kill cancer cells by targeting specific cancer-associated proteins, or antigens. CAR-T cell therapy is highly effective against haematological malignancies, but faces challenges in solid tumours due to the immunosuppressive effects of the tumour microenvironment. Often, combination therapies, such chemotherapy and checkpoint blockage, are used with CAR-T to improve efficacy.

The University of Strathclyde (UoS) in Glasgow, and ScreenIn3D Ltd, are using custom CAR-T products supplied by AMSBIO to perform novel immune-oncology assays in 3D microfluidic cancer models.

To investigate CAR-T efficacy, their off-target cytotoxicity and synergistic effects when used in combination assays, UoS and ScreenIn3D researchers developed novel miniaturised screening assays that use very small amounts of CAR-T cells in 3D complex in vitro models of solid tumours on a chip.

This exciting technological advance by UoS and ScreenIn3D researchers is described in detail in a recently published technical article: https://bit.ly/3iASDy0

AMSBIO offers a custom service that enables researchers to take advantage of the astonishing clinical breakthroughs achieved with CAR-T cells in various haematological malignancies. Drawing upon its expertise in monoclonal antibody development (rabbit and mouse), AMSBIO can help you design, plan and execute your CAR-T study, whether you are in the preclinical, clinical or proof of concept stage. The AMSBIO CAR-T platform is highly adaptable to your needs and starting materials, allowing you to start with a target molecule (Phase I) or antibody (Phase II). As part of their custom CAR-T development service, AMSBIO construct the single chain variable fragment (ScFv), transfer it into a CAR lentivector of your choice, make lentivirus and transduce activated human (or mouse) T cells. After the CAR-T cells proliferate, the cytotoxicity is measured in a real time assay, CAR expression analysed and cytokine production quantified.

More information online

Latest News

Lab Asia 33.4 - August 2026

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
FM approval strengthens intelligent fixed gas detection for refineries and petrochemical plants
Explore more Arrow
Pollution Solutions Online
Slurry grant a fossil fuel failure?
Explore more Arrow
Petro Online
Precision by weight: The critical role of gravimetric blending in fuel certification
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow